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Available online 10 January 2019Introduction: Troponin elevations after intermediate-to-high risk noncardiac surgery are common and can pre-
dict mortality. However, the prognostic value for early and late major adverse cardiovascular events (MACE) is
less well investigated. The authors evaluated the relationship between postoperative troponin release and
MACE in the ﬁrst year after noncardiac surgery.
Methods: This observational cohort registry comprised data of patients aged ≥60 years undergoing intermediate-
to-high risk noncardiac surgery between July 2012 and 2015, at the Erasmus University Medical Center,
Rotterdam, the Netherlands. High-sensitivity troponin Twasmeasured on day 1 to 3 after surgery. Peak troponin
values were divided into four categories: b14 ng·L−1, 14–49 ng·L−1, 50–149 ng·L−1 and ≥150 ng·L−1. The
primary endpoint MACE was deﬁned as the occurrence of myocardial infarction, angina, revascularization
therapy or cerebrovascular accident in the ﬁrst year after surgery. The incidence of MACE and all-causemortality
was calculated using Kaplan-Meier estimates. Cox regression was used to estimate risks for both endpoints.
Results: In total, 3085 patients were included for analyses and peak troponin elevation above 14 ng·L−1 was
present in 1678 (54.4%) patients. The overall incidence for one-year MACE was 5.8% (3.4%, 6.1%, 10.4%
and 40.6% per increasing troponin category) with adjusted HR (95% CI) 1.32 (0.85–2.06), 2.53 (1.42–4.53)
and 10.24 (5.91–17.75) for the consecutive increasing categories. One-year mortality occurred in 14.6%
and showed a similar stepwise increase with adjusted HR (95% CI) 1.25 (0.98–1.60), 2.39 (1.72–3.32) and
3.79 (2.60–5.54).
Conclusion: Our dataset demonstrates a graded relationship between postoperative troponin release and occur-
rence of MACE in the ﬁrst year after intermediate-to-high risk noncardiac surgery.chusetts
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Over the years, many strategies have been explored to identify
patients at risk for adverse cardiac outcomes after surgery. In 1990
Mangano et al. showed that perioperative myocardial ischemia is
associated with an increased risk for cardiovascular events following
noncardiac surgery [1]. To this day, focus on cardiac ischemia and its
consequences remain a topic of interest, with troponin being the most
sensitive marker for cardiac injury at this moment [2].
Routine troponin surveillance after intermediate-to-high risk non-
cardiac surgery is an accepted and upcoming tool to identify patients, USA
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us University Medical
erlands.
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smc.nl (R.J. Stolker),
an open access article underat risk for postoperative mortality [3]. However, proportions of patients
with elevated troponin vary within the range of 6–73% in literature [4].
The pathophysiology and thereby therapeutic consequence of troponin
elevations is still under debate in both literature and in daily clinical
practice. In the general population, troponin release is related to stable
coronary artery disease [5,6] and elevation is recognized as an indepen-
dent predictor of adverse cardiovascular outcome [6]. In the surgical
population, attention has been focused predominantly on mortality,
and troponin release has been shown to be an independent predictor
for early and late onset mortality after surgery [3,7,8]. However, the
prognostic value for early and late major adverse cardiovascular events
is less well investigated. Ekeloef et al. investigated the association be-
tween postoperative troponin release andmajor adverse cardiac events
through a systematic review and meta-analysis, but was only able to
include 3 articles on one-year follow up and all were in an orthopaedic
surgical population [4]. In this cohort study, we evaluated the relation-
ship between postoperative troponin release and the occurrence of
major adverse cardiovascular events in a large cohort in the ﬁrst year
after surgery.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Patient selection
Between July 2012 and July 2015, all consecutive patients aged 60 years and older, un-
dergoing intermediate-to-high risk noncardiac surgery at the Erasmus University Medical
Center (Erasmus MC), were registered in an ongoing clinical routine troponin registry
[9,10]. Intermediate-to-high risk noncardiac surgery included the following operations:
major abdominal, genitourinary, vascular, orthopaedic and neurologic surgery [11].
Expected length of surgery had to exceed at least 1 h and an expected postoperative in-
hospital stay ≥24 h. This observational study was reviewed by the Medical Ethical
Committee of Erasmus University, Rotterdam, the Netherlands who approved the non-
interventional character of the present study. Patients were not subjected to acts, neither
were any mode of behaviour imposed, otherwise than as part of their regular treatment
and there was no need for extra blood sampling. Therefore, according to Dutch law,
written informed consent for a patient to be enrolled in this study was not required. The
study was conducted in compliance with the Helsinki declaration [12].
2.2. Postoperative troponin measurements
In this cohort registry, routine troponinmeasurement on day 1 to 3 after surgerywere
performed as standard clinical care in patients aged 60 years and older undergoing
intermediate-to-high risk noncardiac surgery at the Erasmus University Medical Center.
Fifth generation high-sensitivity troponin T assay was used (Elecsys® Troponin T hs
(TnT-hs), Roche Diagnostics, Basel, Switzerland).
Myocardial injury was deﬁned as a peak troponin elevation above the 99th percentile
of 14 ng·L−1 in the ﬁrst 3 days after surgery. For analysis, troponin levels were divided into
four categories, as previously published [9,10]. The hsTnT thresholds were based on the
manufacturers andprevious determined postoperative prognostic values of the fourth gen-
eration assay [8]. The lowest thresholdwas the manufacturer's 99th percentile of a normal
population, i.e. 14 ng·L−1 [13]. The second was based on the 0.03 ng·mL−1 threshold of
the fourth generation assay's abnormal elevations, which is equivalent to 50 ng·L−1 of
the ﬁfth assay [13]. The highest threshold was extrapolated from the highest threshold in
the Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) study [8],
which was 10 times the threshold of an abnormal troponin elevations, i.e. 140 ng·L−1
for the 5th generation, rounding off to 150 ng·L−1. The ﬁrst category (0–13 ng·L−1) is con-
sidered normal, the second (14–49 ng·L−1) and third (50–149 ng·L−1) being minor andTable 1
Baseline characteristics.
hsTnT values (ng L−1)
b14 14–49
N = 1407 N = 1312
Age (IQR) 66 (63–71) 71 (66–77)
Gender (M) 694 (49.3) 864 (65.9)
Hypertension 658 (46.8) 778 (59.3)
Coronary artery disease 138 (9.8) 262 (20.0)
Myocardial infarction 86 (6.1) 198 (15.1)
Cerebrovascular accident 172 (12.2) 232 (17.7)
PAD 105 (7.5) 183 (13.9)
COPD 151 (10.7) 209 (15.9)
Diabetes mellitus 248 (17.6) 341 (26.0)
Current or history of heart failure 22 (1.6) 97 (7.4)
Renal failure 23 (1.6) 145 (11.1)
Revised cardiac risk index
0 risk factors 758 (53.9) 470 (35.8)
1 risk factor 459 (32.6) 445 (33.9)
2 risk factors 150 (10.7) 236 (18.0)
≥3 risk factors 40 (2.8) 161 (12.3)
Medication use
Beta blockers 418 (29.7) 552 (42.1)
Statins 515 (36.6) 646 (49.2)
ACE inhibitor 267 (19.0) 350 (26.7)
Aspirin 337 (24.0) 473 (36.1)
Oral anticoagulants 93 (6.6) 205 (15.6)
Diuretics 316 (22.5) 419 (31.9)
Insulin 71 (5.0) 149 (11.4)
Type of surgery
General 193 (13.7) 180 (13.7)
Orthopedics 205 (14.6) 190 (14.5)
Urology/gynecology 265 (18.8) 183 (13.9)
Vascular 283 (20.1) 368 (28.0)
Other 461 (32.8) 391 (29.8)
Emergency surgery 47 (3.3) 101 (7.7)
Length of surgery (IQR) 211 (155–290) 202 (150–2
Table 1 describes numbers of patients (%). PAD= peripheral arterial disease. COPD= chronic o
Length of surgery is represented in minutes.moderate myocardial injury respectively, and the fourth (≥150 ng·L−1) being approxi-
mately ten times the upper limit of the normal reference value of 14 ng·L−1.
2.3. Data collection and follow-up
Data were extracted from the electronic hospital patient information system. Patient
characteristics include age, sex, type of surgery, past medical history, use of medication,
length of hospital admission and discharge location. Past medical history focused on car-
diovascular risk proﬁle, including previous myocardial infarction, coronary artery disease,
lower extremity arterial disease, renal failure (as reported in medical ﬁle or creatinine
values N177 μmol·L−1), chronic heart failure and cerebrovascular accident. Follow-up
data for the primary outcome were acquired from patients' own report on cardiovascular
events either throughquestionnaires sent out by post 1 year after their initial surgery or, in
case of a non-response, by telephone interview. In case of a total non-response, the elec-
tronic hospital patient information system was used as best alternative possible, and the
date of last review or consultation was used to calculate the clinical follow-up time. All
patient-reported events were checked in the electronic hospital patient information sys-
tem if possible or (if permission was given) through contacting one's general practitioner
or other hospitals. Information on survival status was obtained from the civil registries.
2.4. Outcome
The primary outcome was the occurrence of major adverse cardiovascular events
(MACE) within one year after surgery, obtained as written above. MACE was deﬁned as
the composite endpoint of myocardial infarction, angina, coronary revascularization
(both percutaneous coronary intervention (PCI) and coronary artery bypass graft
(CABG)) or cerebrovascular accident. Hospital admission was required for all events. The
secondary endpoint was all-cause mortality during one-year follow-up.
2.5. Statistical analysis
Categorical data are presented as numbers and percentages. Continuous data are de-
scribed asmeanwith standard deviation ormedianwith interquartile range if distribution
was not normal. Baseline characteristics were compared between all four categories of
troponins, using chi-square analyses for categorical data and Kruskal Wallis test for con-
tinuous data. Incidence of MACE and all-cause mortality at one year after surgery was50–149 ≥150 P-value
N = 267 N = 99
73 (67–78) 73 (66–77) b0.001
181 (67.8) 70 (70.7) b0.001
192 (71.9) 70 (70.7) b0.001
80 (30.0) 47 (47.5) b0.001
69 (25.8) 34 (34.3) b0.001
67 (25.1) 25 (25.3) b0.001
46 (17.2) 21 (21.2) b0.001
58 (21.7) 18 (18.2) b0.001
115 (43.1) 38 (38.4) b0.001
41 (15.4) 15 (15.2) b0.001
88 (33.0) 27 (27.3) b0.001
b0.001
38 (14.2) 19 (19.2)
83 (31.1) 25 (25.3)
75 (28.1) 23 (23.2)
71 (26.6) 32 (32.3)
145 (54.3) 53 (53.5) b0.001
153 (57.3) 65 (65.7) b0.001
68 (25.5) 40 (40.4) b0.001
123 (46.1) 51 (51.5) b0.001
49 (18.4) 27 (27.3) b0.001
127 (47.6) 41 (41.4) b0.001
71 (26.6) 20 (20.2) b0.001
29 (10.9) 15 (15.2) 0.587
35 (13.1) 5 (5.1) 0.062
28 (10.5) 8 (8.1) b0.001
88 (33.0) 30 (30.3) b0.001
87 (32.6) 41 (41.4) 0.062
61 (22.8) 31 (31.3) b0.001
74) 196 (141–275) 179 (110–292) 0.003
bstructive pulmonary disease. Renal failure is deﬁned as creatinine values N177 μmol·L−1.
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dependent ROC curve and area under the curve (AUC) was calculated through the
Kaplan Meier method for MACE at one-year follow-up [14,15]. Both univariate and mul-
tivariate COX regression hazard ratios were calculated for the occurrence of all-cause
mortality and MACE for all different categories of troponins. Peak troponin levels
below 14 ng·L−1 was used as the reference category. Multivariable analyses included
sex, age, coronary heart disease, diabetes, cerebrovascular accident, renal failure, chronic
heart failure and emergency surgery. Sensitivity analyses were performed between pa-
tients who could be reached through questionnaires by post or telephone, and patients
whose follow-up data was obtained from the electronic hospital patient information sys-
tem. A two-sided P value of b0.05 was considered signiﬁcant. Analyses were performed
using IBM SPSS 21.0 statistical software (SPSS Inc., Chicago, Illinois, USA). R Studio
Version 1.0.153 was used for survival analysis and time-dependent AUC analysis [15,16].
3. Results
3.1. Study population
A total of 3085 (72.5%) of 4253 consecutive patients undergoing sur-
gery fulﬁlled the inclusion criteria of at least one postoperative troponin
measurement (see online appendix A). Baseline characteristics are pre-
sented in Table 1. In total, 1678 (54.4%) patients had an elevated peak
troponin measurement of 14 ng·L−1 and above during the ﬁrst 3 days
after surgery. Of these patients, 78.2%, 15.9%, 5.9% had peak troponin
levels of 14 to 49 ng·L−1, 50 to 149 ng⋯L−1 and ≥150 ng·L−1, respec-
tively. With increasing levels of peak troponin, patients were of older
age,male sexwas predominant andmore patients had an extensive his-
tory of cardiovascular disease.
3.2. Major adverse cardiac event
At one year after surgery 2634 patients were still alive and at
least one year of follow-up was obtained for 2448 patients, of whom
2135 (87.2%) were contacted through written questionnaire or by
phone. Of the remaining patients and patients who died, informationTable 2
Incidence, hazard ratios, median time to event and discharge in days (IQR, 25th–75th percenti
A
hsTnT values (ng·L−1)
b14 14–49
N = 1407 N = 1312
MACE at 1 year (%) 44 (3.4) 73 (6.1)
HR (95% CI)1 1 1.70 (1.12–2.58)
HR (95% CI)2 1 1.32 (0.85–2.06)
Median time to event (IQR) 160 (48–254) 76 (13–251)
In-hospital MACE (%) 26 (1.8) 32 (2.4)
Median time to event (IQR) 3 (2–5) 9 (4–14)
Mortality at 1 year (%) 144 (10.3) 187 (14.3)
HR (95% CI)1 1 1.34 (1.07–1.68)
HR (95% CI)2 1 1.25 (0.98–1.60)
Median time to event (IQR) 162 (73–255) 101 (42–224)
Panel A describes events and one-minus Kaplan-Meier estimates (%) of MACE and all-cau
HR1: hazard ratios are calculated with a Univariate Cox regression model.
HR2: hazard ratios are calculated with a Multivariate Cox regression model.
Median time to event is represented in days (IQR).
For in hospital MACE and discharge location absolute numbers (%) are presented.
B
hsTnT values (ng·L−1)
b14 14–49
N = 1407 N = 13
Length hospital stay (median(IQR)) 6 (4–9) 7 (4–13
Discharge location (%)
Home 1262 (89.7) 1064 (8
Nursing home 81 (5.8) 155 (11
Peripheral hospital 41 (2.9) 37 (2.8
In hospital death 9 (0.6) 29 (2.2
Unknown 14 (1.0) 27 (2.1on follow-up was extracted from the hospital's electronic patient data
management system.
The primary outcome one-year MACE occurred in 178 (5.8%)
patients of whom 135 (75.8%) with troponin values of 14 ng/L
and above. In total, 76 patients experienced a myocardial infarction,
68 patients had angina requiring hospitalization, 54 patients had a cere-
brovascular accident and 49 patients underwent revascularization ther-
apy (see online appendix B). MACE wasmore common in patients with
higher troponin levels after surgery (3.4%, 6.1%, 10.4% and 40,6% for in-
creasing levels of troponin (P b 0.01, Fig. 1, Table 2A)). Cumulative inci-
dence of MACE showed the same relationship across the different types
of surgery (online appendix C). The AUCwas 0.70. Time to eventwas in-
versely related to peak troponin after surgery (Table 2). The majority of
the events occurred in the ﬁrst fewmonths after surgery with approxi-
mately 50%of all eventswithin index hospitalization (Table 2). Adjusted
hazard ratios for occurrence of 1-year MACE were: aHR 1.32 (95% CI,
0.85–2.06), 2.53 (95% CI, 1.42–4.53) and 10.24 (95% CI, 5.91–17.75)
for increasing levels of peak troponin (Table 2).
Sensitivity analyses were performed to assess the effect of patients
who responded through questionnaire compared to follow-up through
the electronic patient record system: aHR 0.78 (95% CI, 0.40–1.55),
2.00 (95% CI, 0.78–5.07) and 5.43 (95% CI, 2.01–14.66) in the responders
group compared to 1.87 (95% CI, 1.02–3.45), 2.50 (95% CI, 1.16–5.40)
and 14.95 (95% CI, 7.21–31.02) for non-responders throughout in-
creasing levels of peak troponin elevation.
3.3. All–cause mortality
In total, 451 (14.6%) patients died within the ﬁrst year after surgery
andmedian time to deathwas 99 (IQR, 35 - 222) days. Cumulative inci-
dence formortality is shownby KaplanMeier estimates at 6months and
1-year follow-up (Fig. 2, Table 2A). In the reference category of peak
troponin values b14 ng⋯L−1, cumulative incidence was 10,3% whichle, Tukey's Hinges) for MACE and all-cause mortality in the ﬁrst year postoperative.
50–149 ≥150 P-value
N = 267 N = 99
25 (10.4) 36 (40.6) b0.001
3.42 (2.04–5.75) 14.83 (9.13–24.10)
2.53 (1.42–4.53) 10.24 (5.91–17.75)
10 (3−22) 3 (1−11)
17 (6.4) 26 (26.3) b0.001
8 (3–18) 2 (1–4)
74 (27.9) 46 (46.5) b0.001
2.62 (1.96–3.49) 4.50 (3.19–6.35)
2.39 (1.72–3.32) 3.79 (2.60–5.54)
54 (14–183) 27 (7–63)
se mortality in patients. P-values are calculated through Log-Rank analyses.
50–149 ≥150 P-value
12 N = 267 N = 99
) 11 (6–19) 11 (6–23) b0.001
b0.001
1.1) 177 (66.3) 55 (55.6)
.8) 53 (19.9) 13 (13.1)
) 11 (4.1) 6 (6.1)
) 23 (8.6) 25 (25.3)
) 3 (1.1) 0 (0.0)
Fig. 1. Kaplan Meier of MACE. Estimates calculated using the one-minus Kaplan-Meier
approach. The lines represent the four different peak troponin categories: b14 ng·L−1
[coral], 14–49 ng·L−1 [green], 50–149 ng·L−1 [blue] and N150 ng·L−1 [purple].
Fig. 2. Kaplan Meier of all-cause Mortality. Estimates calculated using the one-minus
Kaplan-Meier approach. The lines represent the four different peak troponin categories:
b14 ng·L−1 [coral], 14–49 ng·L−1 [green], 50–149 ng·L−1 [blue] and N150 ng·L−1
[purple].
11K.H.J.M. Mol et al. / International Journal of Cardiology 280 (2019) 8–13increased to 14.3%, 27.9% and 46.5% for higher troponin values (P b 0.01,
Table 2). After adjustment, hazard ratios remained signiﬁcant: aHR
1.25 (95% CI, 0.98–1.60), 2.39 (95% CI, 1.72–3.32) and 3.79 (95% CI,
2.60–5.54) for increasing levels of peak troponin elevation (Table 2).
3.4. Discharge location
The majority of patients were sent home after discharge across all
categories of peak troponin. An inverse relationship with increasing
peak troponin can be seen, with 89.7% for values b14 ng·L−1 and
55.6% for values N150 ng·L−1 (Table 2B). In-hospital death and dis-
charge to a nursing home was more often seen in patients within the
higher troponin categories.
4. Discussion
This study shows that patients with troponin elevation after
intermediate-to-high risk non-cardiac surgery have an increased risk
for MACE and all-cause mortality in the ﬁrst year following surgery.
There is a graded association between peak troponin elevation and inci-
dence of both MACE and death. Furthermore, time to event is inversely
related to increasing levels of troponin with approximately half of all
cardiovascular events occurring after discharge.
More than half of the patients in our study had an elevated peak tro-
ponin measurement above the 99th percentile. The therapeutic conse-
quences of postoperative troponin elevations are frequently debated
amongst clinicians. A systematic review andmeta-analysis on postoper-
ative troponin release published in 2016 concluded that higher troponin
concentrations were associated with increased incidence in death and
major adverse cardiac events within one-year after surgery [4]. These
increased risks are in linewith our ﬁndings regarding both adverse out-
comes. The distinctive feature of our study is the addition of the graded
association forMACEwith increasing levels of peak troponin in contrast
to troponin elevation as a dichotomized value below or above the 99th
percentile threshold for the speciﬁc assay used. The three studies that
reported on the association between postoperative troponin elevation
and 1-year MACE, with varying outcome deﬁnitions used for adverse
cardiac events,were limited to patients undergoing orthopaedic surgery
[17–19]. In our study, we included all types of intermediate-to-high risk
noncardiac surgery to generate results for a general surgical population.
Furthermore, different cut off-values of different troponin assays are
used which limit direct comparisons. In our overall cohort, patients
had a 5.8% risk of developing MACE. In the literature, the proportion of
patients experiencingMACE at one year after noncardiac surgery varies
between 4% and 32% [4]. Our results show a clear stepwise increase in
incidence with increased levels of troponin.
Association between troponin elevation and occurrence of all-cause
mortality within one year after surgery showed the same relationship
with increasing levels of peak troponin expected based upon previous
work [4,20–23]. Similar to our results, investigators of the VISION
study group and van Waes and colleagues found increasing hazards
for moderate and major peak troponin elevation on early postoperative
complications [20,22]. The VISION study group primarily focused on the
association between different levels of troponin elevation and 30-day
mortality. Our study adds that troponin shows to be an independent
predictor for long-term cardiovascular events for troponin elevations
above 50 ng/L. In a more recent paper, the VISION trial showed that
only 11% of subjects had troponin elevation of a non-ischemic etiology
[22], suggesting an underlying cardiovascular disease. Van Waes
reported that in 38% of patients with postoperative myocardial injury
receiving cardiac consultation postoperatively, an intervention was ini-
tiated (e.g. change in medication, coronary angiography). In our data,
approximately half of all events occurred within index hospitalization.
Median time to event in the highest troponin category (≥150 ng·L−1)
was 3 days. Thence, troponin elevation itself is likely to be part of
these events rather than being a predictor for the occurrence of MACE
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troponin elevations as a symptom rather than a prognostic factor.
For patients who experience MACE with peak troponin elevation be-
tween 50 and 149 ng·L−1, median time to event was 10 days after
surgery and hazards remained throughout multivariate analysis. In
these patients, troponin elevations could be assumed to be of prog-
nostic value. If so, this particular group, for whom cardiac consulta-
tions are frequently requested, can be a target group for additional
preventive strategies [4,20]. Recently, investigators of the MANAGE
trial published on management of patients with postoperative tropo-
nin elevation. [24] They were able to show a relative reduction in
incidence of major vascular events with 27% by adding dabigatran to
patients' medical treatment. The results of this study as well as both
of the VISION andMANAGE trial, suggest a relationship between tropo-
nin elevation and atherosclerotic cardiovascular diseases, albeit in
opposite ways.
Troponin has beenwell identiﬁed as a diagnostic and prognostic tool
for adverse cardiovascular events in patients with established stable
coronary artery disease [6,25,26]. Current coronary arteriosclerotic re-
search suggests that the pathophysiological process underlying tropo-
nin elevation in stable coronary artery disease are repetitive cycles of
subclinical rupture and/or erosion with subsequent microembolisation
of non-calciﬁed plaques and repair and that 60% of ischemic coronary
events are precipitated by plaque rupture followed by thrombosis
[6,27].
Additionally, adding troponin to variables of established risk score
improves prediction of cardiovascular death and cardiovascular disease.
We endorse the suggestion that postoperative troponin release can be
used in risk stratiﬁcation [3,4,28,29].
4.1. Limitations
There are several limitations to this study. First, while monitoring
troponin elevations, preoperative troponin values were not measured
routinely, so delta troponin could not be calculated.
Secondly, 922 (35%) patients could not be reached through written
or telephone questionnaire, and their information on follow-up was
only limited to our University Hospital. Third, patients' events were
self-reported. However, we asked for events for which a hospital admis-
sion was required to improve the quality of the reported events and
moreover, self-reported events have been checked. Furthermore,
we did not have information on cause of death, which could have
added valuable information. We also had to exclude approximately
one-fourth of patients who enrolled in this study due to poor protocol
adherence for routine troponin measurement in the beginning.
After implementing electronic laboratory requisitions, protocol adher-
ence improved. Sensitivity analyses on peak troponin levels showed
similar results after implementation of electronic orders. Last, the
present study is a single center cohort registration in a University
Hospital with a corresponding patient population, which may limit
generalizability.
5. Conclusion
This paper describes a set of data providing information on long-
term follow-up in patients with myocardial injury after intermediate-
to-high risk noncardiac surgery. While many studies have demon-
strated a relation between troponin elevation and mortality, little
is known about the effect on cardiovascular morbidity. Our results
showed a signiﬁcant association between postoperative troponin
release and MACE in the ﬁrst year after intermediate-to-high risk non-
cardiac surgery and a higher risk for (future) cardiovascular events
and consequentmorbidity in patients withmoderate and high troponin
elevations.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcard.2019.01.035.Abbreviations
MACE Major Adverse Cardiovascular Events
hsTnT High-sensitivity troponin T
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